Publications
SITC 2022
November, 2022
Dr. Christine Chung presents new clinical data on CUE-101.
Many thanks to Dr. Chung, the Moffitt Cancer
Center and their Marketing Team
Dr. Christine Chung presents new clinical data on CUE-101.
Many thanks to Dr. Chung, the Moffitt Cancer
Center and their Marketing Team
Noteworthy Publications
Induced, but not natural, regulatory T cells retain phenotype and function following exposure to inflamed synovial fibroblasts
October, 2020
Yang S, Zhang X, Chen J, Dang J, Liang R, Zeng D, Zhang H, Xue Y, Liu Y, Wu W, Zhao J, Wang J, Pan Y, Xu H, Sun B, Huang F, Lu Y, Hsueh W, Olsen N, Zheng SG. Induced, but not natural, regulatory T cells retain phenotype and function following exposure to inflamed synovial fibroblasts. Sci Adv. 2020 Oct 28;6(44):eabb0606.
Full textEpigenetic conversion of conventional T cells into regulatory T cells by CD28 signal deprivation
May, 2020
Mikami N, Kawakami R, Chen KY, Sugimoto A, Ohkura N, & Sakaguchi S. Epigenetic conversion of conventional T cells into regulatory T cells by CD28 signal deprivation, Proc. Natl. Acad. Sci. 2020. 117 (22) 12258-12268.
Full textCritical Role of TGF-β and IL-2 Receptor Signaling in Foxp3 Induction by an Inhibitor of DNA Methylation
February, 2018
Freudenberg K, Lindner N, Dohnke S, Garbe AI, Schallenberg S, Kretschmer K. Critical Role of TGF-β and IL-2 Receptor Signaling in Foxp3 Induction by an Inhibitor of DNA Methylation, Front. Immunol. 2018 Feb 2;9:125.
Full textAntigen-specific transforming growth factor β–induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance
May, 2012
Kong N, Lan Q, Chen M, Wang J, Shi W, Horwitz DA, Quesniaux V, Ryffel B, Liu Z, Brand D, Zou H, Zheng SG. Antigen-specific transforming growth factor β-induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance. Arthritis Rheum. 2012 Aug;64(8):2548-58.
Full textConversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3
December, 2003
Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003 Dec 15;198(12):1875-86.
Full text2025 Publications & Presentations
Cytokines (ICIS) Annual Meeting
November, 2025
Poster Presentation: CUE-401: A Novel TGF-beta/IL-2 Fusion Protein for the Induction & Expansion of FOXP3+ Regulatory T Cells
Continue readingT-cell receptor/CD28-targeted immunotherapeutics selectively drive naive T-cell expansion to generate functional HIV-specific responses
August, 2025
Journal of Virology; August 5, 2025 DOI: 10.1128/jvi.00188-25
Continue readingASGCT Annual Meeting
May, 2025
Poster Presentation: Leveraging Immuno-STAT™ stimulation via TCR and IL-2 signaling to specifically control CAR T cell expansion and persistence in vivo
Continue reading2024 Publications & Presentations
SITC Annual Meeting
November, 2024
Oral Presentation: A phase 1 dose-escalation and expansion study of CUE-101 as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer
Continue readingSITC Annual Meeting
November, 2024
Poster Presentation: A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc T cell engager in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
Continue readingASCO Annual Meeting
June, 2024
Oral Presentation: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). Presented by, Douglas R. Adkins, M.D., Professor of Medicine, Washington University School of Medicine, St. Louis, and a principal investigator participating in the CUE-101 clinical trial
Continue readingASCO Annual Meeting
June, 2024
Poster Presentation: A phase 1 dose escalation and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in HLA-A*0201- positive patients with WT1-positive recurrent/metastatic cancers
Continue reading2023 Publications & Presentations
SITC Annual Meeting
November, 2023
Poster Presentation: A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
Continue readingSITC Annual Meeting
November, 2023
Poster Presentation: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients
Continue readingASCO Annual Meeting
June, 2023
Poster Presentation: A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
Continue reading2022 Publications & Presentations
SITC Annual Meeting
November, 2022
Poster Presentation: A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
Continue readingSITC Annual Meeting
November, 2022
Poster Presentation: A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
Continue readingSITC Annual Meeting
November, 2022
Poster Presentation: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies
Continue readingAmerican Society of Clinical Oncology (ASCO)
June, 2022
Poster Presentation: A Phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
Continue readingFrontiers in Cancer Immunotherapy Conference 2022 NYAS
May, 2022
Poster Presentation: CUE-102 Selectively Activates and Expands WT1-Specific T Cells for the Treatment of Patients with WT1+ Malignancies
Continue readingBPS Annual Meeting
February, 2022
Poster Presentation: Integration of IL-2 signaling at the immunological synapse
Continue reading2021 Publications & Presentations
SITC Annual Meeting
November, 2021
Poster Presentation: A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
Continue readingSITC Annual Meeting
November, 2021
Poster Presentation: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies
Continue readingT-Cell receptor-specific immunotherapeutics drive selective in vivo HIV and CMV-specific T-cell expansion in humanized mice
October, 2021
The Journal of Clinical Investigation; October 21, 2021 DOI: 10.1172/JCI141051
Continue readingPeptide‑HLA‑based immunotherapeutics platforms for direct modulation of antigen‑specific T cells
September, 2021
Nature Portfolio, Scientific Reports; September 28, 2021 DOI: 10.1038/s41598-021-98716-z
Continue readingFOCIS Annual Meeting
June, 2021
Video: CUE-401: A novel IL-2/TGF-beta fusion protein for the induction of CD4+ FOXP3+ regulatory T cells
Continue readingFrontiers in Cancer Immunotherapy Conference
May, 2021
Poster Presentation: Immuno-STAT™ (Selective Targeting and Alteration of T cells) Platform: Targeting Tumor Heterogeneity and Tumor Escape Mechanisms
Continue readingASIT Summit
January, 2021
Presentation: Directly Targeting Autoantigen-Specific T cells with Immuno-STATs
Continue reading2020 Publications & Presentations
In vivo detection of antigen-specific CD8+ T cells by immuno-positron emission tomography
September, 2020
Nature Methods 2020; September 14, 2020 DOI: 10.1038/s41592-020-0934-5
Continue readingPEGS Boston
August, 2020
Video Poster Presentation: Neo-STAT™: A new biologics platform for selective targeting of tumor-specific T cells with enhanced antigen modularity
Continue readingMechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex
June, 2020
PLOS One 2020; June 4, 2020 DOI: 10.1371/Journal PONE.0233578
Continue readingCUE-101, a Novel HPV16 E7 pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies
January, 2020
Clinical Cancer Research 2020; January 21, 2020 DOI: 10.1158/1078-0432.CCR-19-3354
Continue reading2019 Publications & Presentations
SITC Annual Meeting
November, 2019
Poster Presentation: CUE-101, a Novel HPV16 E7:pMHC:IL-2:Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies
Continue readingEyeforpharma Philadelphia
April, 2019
Video: Diagnostic & disease detection to transform biopharma
Continue readingKeystone Symposia
January, 2019
Poster Presentation: CUE-101, a novel Fc fusion protein for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies
Continue reading